Janssen Biotech, part of US healthcare giant Johnson & Johnson (NYSE: JNJ), has entered into a worldwide license deal for the co-development and commercialization of PTG-200.
The drug is US biotech firm Protagonist Therapeutics' (Nasdaq: PTGX) first-in-class, oral peptide interleukin (IL)-23 receptor antagonist for all indications including inflammatory bowel disease (IBD), and news of the deal sent the firm’s shares skyrocketing 72.5% to $14.27 in early trading today.
PTG-200 is expected to enter Phase I clinical testing in normal healthy volunteers in the second half of 2017. The agreement builds upon a Johnson & Johnson Innovation – JJDC, Inc Series B venture financing from 2013 in support of the discovery and development of Protagonist's pipeline of oral peptide therapeutics.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze